Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Behçet's Disease and Eosinophil Cationic Protein

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Didem Arslan Tas, Cukurova University
ClinicalTrials.gov Identifier:
NCT01584778
First received: April 24, 2012
Last updated: April 25, 2012
Last verified: April 2012

April 24, 2012
April 25, 2012
January 2002
December 2002   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01584778 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Behçet's Disease and Eosinophil Cationic Protein
The Serum Eosinophil Cationic Protein Levels in Behçet's Disease and Its Relation to the Clinical Activity

Eosinophil cationic protein (ECP) is a matrix protein of eosinophils and has been reported to reflect eosinophil activity. Few studies have examined the role of eosinophils in the pathogenesis of Behçet's disease. The purpose of the present study is to investigate the serum ECP levels in BD and its relation to clinical activity.

Behçet's disease (BD) is a systemic vasculitis, characterized by recurrent oral aphthae, genital ulcers, uveitis, skin lesions, arthritis, gastrointestinal and neurologic manifestations. There has been a growing interest in research on the pathogenesis of the disease. Eosinophils has been implicated in the vascular injury associated with several vasculitis syndromes like Churg Strauss syndrome, temporal arteritis and Henoch-Schonlein purpura. In Behçet patients, serum IgE and eosinophils have been reported to be comparable with the controls but eosinophil activity has not been studied extensively. Eosinophil cationic protein (ECP) is a matrix protein of specific granules of eosinophils with considerable capacity to damage tissue and cells and has been reported to reflect eosinophil activity. Increased serum levels of ECP has been reported in patients with seasonal allergic rhinitis. Several immunomodulatory features of ECP has been reported, such as inhibition of the proliferative T-lymphocyte response to antigen, immunoglobulin production, proliferation of plasma cell lines and upregulation of ICAM-1. Procoagulant effects of ECP has also been reported. The present study was conducted in patients without usage of any confounding drugs that can effect serum ECP levels. The purpose of this study was to investigate the serum ECP levels in BD and its relation to the clinical activity.

Forty-seven consecutive patients with BD (22 active, 25 inactive) meeting International Study Group Criteria , 21 age and sex matched patients with allergic rhinitis and 21 apparently healthy controls were evaluated prospectively in Rheumatology-Immunology Outpatient Clinic. Clinical activity was defined according to the criteria proposed by "Behcet's Disease Research Committee of Japan" . Activity scoring was made according to the "Behçet's Disease Research Committee of Japan" which was proposed in 1994. Organ involvements of the patients were summarized.

Patients on corticosteroids or immunosuppressives were excluded. Colchicine was stopped 10 days prior to the blood collection in inactive patients. Blood was drawn from the active patients before starting treatment. Cases with any allergy history or parasitosis were excluded.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Consecutive Behçet patients of the outpatient clinic of the Rheumatology-Immunology Department of University Hospital

Behçet's Disease
Other: eosinophil cationic protein
Serum eosinophil cationic protein levels
Other Name: ECP
  • Behçet patients
    Intervention: Other: eosinophil cationic protein
  • Healthy controls
    Intervention: Other: eosinophil cationic protein
  • Allergic rhinitis (diseased) controls
    Intervention: Other: eosinophil cationic protein
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
47
December 2002
December 2002   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Consecutive Behçet patients who gave the written informed consent were included.

Exclusion Criteria:

  • Patients on corticosteroids or immunosuppressives were excluded.Cases with any allergy history or parasitosis were excluded.
Both
16 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Turkey
 
NCT01584778
TF.00.U.32.
No
Didem Arslan Tas, Cukurova University
Cukurova University
Not Provided
Study Chair: Hüseyin TE Ozer, Assoc. Prof. Cukurova University, Faculty of Medicine, Rheumatology-Immunology Department
Study Director: Eren Erken, Prof. Dr. Cukurova University, Faculty of Medicine, Rheumatology-Immunology Department
Cukurova University
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP